{
    "paper_id": "PMC7136878",
    "metadata": {
        "title": "Drugs supply and pharmaceutical care management practices at a designated hospital during the COVID-19 epidemic",
        "authors": [
            {
                "first": "Wang",
                "middle": [],
                "last": "Ying",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Yu",
                "middle": [],
                "last": "Qian",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Zhu",
                "middle": [],
                "last": "Kun",
                "suffix": "",
                "email": "zhukun@jlu.edu.cn",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "An outbreak of coronavirus disease 2019 (COVID-19) began in Wuhan, Hubei Province, China in December 2019.1According to the Prevention and Control of Infectious Diseases Law of P.R. China, COVID-19 was classified as class B infectious disease, and measures had been taken according to the prevention and control standards of class A infectious disease. COVID-19 was also managed in accordance with Frontier Health and Quarantine Law of P.R. China.2\n",
            "cite_spans": [
                {
                    "start": 106,
                    "end": 107,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 447,
                    "end": 448,
                    "mention": "2",
                    "ref_id": "BIBREF11"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "The Third Hospital of Jilin University (THJU) is managed by China National Health Commission (CNHC) which is a large-scale Grade III-A hospital, with an annual outpatient service of about 1.84 million patients. The hospital was specified as the first provincial-level COVID-19 diagnosis and treatment unit in Jilin Province.3 During COVID-19 outbreak-period, the pressure of medical service has increased. Efficient pharmaceutical practices could provide support for responding to the COVID-19 pandemic.4 The Pharmaceutical Department of THJU has carried out a series of work in terms of drug supply and pharmaceutical service, which has provided effective support for prevention, control and treatments of COVID-19. As of March 31,2020, the mortality rate of patients with COVID-19 in THJU was 0%, the number of infected medical staff was nil.",
            "cite_spans": [
                {
                    "start": 324,
                    "end": 325,
                    "mention": "3",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 503,
                    "end": 504,
                    "mention": "4",
                    "ref_id": "BIBREF15"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "The epidemic attracted the attention of the international communities and was declared the coronavirus a global pandemic by the World Health Organization (WHO) on March 11, 2020. As of April 1,2020, a total of 823,626 confirmed cases had been reported in 202 countries outside China, including 40,598 deaths.5 It is necessary to share practices and experience about epidemic prevention and control. This paper summarized the practices of preventing and controlling COVID-19 in the pharmacy department of THJU to provide reference for those who are facing the same situation.",
            "cite_spans": [
                {
                    "start": 308,
                    "end": 309,
                    "mention": "5",
                    "ref_id": "BIBREF16"
                }
            ],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "In the global fight against the outbreak of COVID-19, countries(areas) are facing with medical staff management challenges:(1)insufficient medical staff, (2)physical and mental health,(3)limited COVID - 19 prevention and control training.(1)Emergency human resource mechanisms could ensure work quality and improve management efficiency.6 The Department of Pharmacy have developed a pharmaceutical personnel echelons system to guarantee sufficient personnel resource. The first team was composed of pharmacists with experiences in fighting against SARS, floods, earthquakes and other emergencies. The second team consisted of clinical pharmacists and laboratory pharmacists who had been responsible for drug supply and dispensing. The first team members were charged with the key responsibilities of advising and educating patients, maintaining a stable supply of pharmaceuticals, and guide suspected cases to fever clinic for screening as required. The second team members received epidemic prevention and control training, under the leadership of the first team members to carry out the work. Otherwise, the pharmaceutical department have selected pharmacists with rich working experience and strong professional abilities as candidates of Wuhan Medical Team.(2)Physical and mental health\n",
            "cite_spans": [
                {
                    "start": 337,
                    "end": 338,
                    "mention": "6",
                    "ref_id": "BIBREF17"
                }
            ],
            "section": "Practice1: man-management",
            "ref_spans": []
        },
        {
            "text": "The COVID-19 outbroke during the Spring Festival---the Chinese traditional festival. Many pharmacists travelled and returned hometown at that time. The pharmacy department designated a pharmacist to take charge of focusing on the staffs' health status. Pharmacists initiatively reported their status every day, including travelled destinations, transportations, temperature, cough symptoms. If anyone came back from suspected epidemic areas was recommended to stay at home 14 days for observation. During an epidemic, false information and rumors can generate serious negative effects to staffs\u2019 mental health, similar to the community prevention and control grid member measures,7 pharmacy department appointed grid emotion managers. Each grid member was responsible for providing emotional management advice and help them: a. Understand COVID-19 correctly; b. Accept the reality of the epidemic; c. Encourage the expression of emotions, guide pharmacists through reading, listening to music, sports and other ways to transfer emotions, to overcome depression, anxiety, insomnia, and distress.(3)Carrying out training.\n",
            "cite_spans": [
                {
                    "start": 680,
                    "end": 681,
                    "mention": "7",
                    "ref_id": "BIBREF18"
                }
            ],
            "section": "Practice1: man-management",
            "ref_spans": []
        },
        {
            "text": "The training mode was mainly online learning, the contents included three aspects: a. Hospital isolation rules training, including: transfer routes, transfer vehicles and dedicated elevators for COVID-19 patients, as well as related medical waste signs. Drugs, patients and pharmacists should move along the designated routes, which help to reduce the risk of nosocomial infection and ensure the supply of drugs.8 b. Prevention training. Pharmacists must learn how to protect themselves from getting infected. A Systematic nosocomial infection prevention and control training have been provided for pharmacists, such as process of use and destruct hats, masks, protective clothing correctly. c. COVID-19 diagnosis and treatment plans training. From January to now, the COVID-19 diagnosis and treatment plans have been updated seven times and several diagnosis and treatment plans webinars have been organized. Through the training, pharmacists can master the isolation system, personal safety protection operation and latest treatment plans. Scientific human resource mechanisms, adequate personal protection and timely training can help employees stabilize the mood and enhance confidence in fighting against the epidemic.",
            "cite_spans": [
                {
                    "start": 412,
                    "end": 413,
                    "mention": "8",
                    "ref_id": "BIBREF19"
                }
            ],
            "section": "Practice1: man-management",
            "ref_spans": []
        },
        {
            "text": "By implementing the man-management guarantee practice, the pharmacology department of THJU has resolve the problem of insufficient medical staff, ensuring the physical and mental health of pharmacists and deepen understanding COVID - 19 prevention and control plans.",
            "cite_spans": [],
            "section": "Practice1: man-management",
            "ref_spans": []
        },
        {
            "text": "During the pandemic, drugs may be in late delivery and short supply due to logistics interruption and production disruptions for various reasons. Otherwise, safe environment is an important guarantee for normal drug supply. To conquer these problems the pharmacy department have carried out four practices:(1)establishing drug supply schemes based on treatment guidelines, (2)Implementing online drug procurement,(3)managing donated medicine,(4)managing environment.(1)Pharmacists have made a list of COVID-19 therapeutic drugs(Table 1\n)to establish COVID-19 prevention and control drug supply schemes based on diagnosis and treatment plans, and the drugs on the list have been procured at first time.\n",
            "cite_spans": [],
            "section": "Practice 2: drug supply management",
            "ref_spans": [
                {
                    "start": 528,
                    "end": 535,
                    "mention": "Table 1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Additionally, Wechat\u00ae (the largest social communication mobile platform in China) groups were established and the director's telephone numbers of the pharmaceutical department have been released on the hospital LAN website, which can help physicians to satisfy the needs of drug supply and use.(2)In order to resolve drug delivery lately in the epidemic, pharmacists have made use of the information network technology, applied the \" IoT Collaborative Service Platform for Drugs\u201d to drug procurement (Fig. 1\nfor workflow). The platform automatically generated orders based on previous sales status from HIS ((Hospital Information System), which could be modified and submitted by pharmacists. The orders were transmitted to suppliers by Internet without delaying, then medicines were delivered according to orders timely. The platform have allowed hospitals and suppliers to share information, optimized the drug procurement workflow, improved the efficiency, saved the labor and material resources, and reduced infectious risk caused by cross contact in the drug purchase process as much as possible.(3)Donated medicine management\n",
            "cite_spans": [],
            "section": "Practice 2: drug supply management",
            "ref_spans": [
                {
                    "start": 501,
                    "end": 507,
                    "mention": "Fig. 1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Affected by the epidemic, a shortage of drugs and protective materials has drawn public attention. THJU received a great many of donations, such as masks, protective clothing and medicine. Therefore, the management of donations is a new task. THJU had formulated a management process (Fig. 2\n) of donations in accordance with laws, and the pharmaceutical department was responsible for managing donated drugs (See Table 2\nfor details).",
            "cite_spans": [],
            "section": "Practice 2: drug supply management",
            "ref_spans": [
                {
                    "start": 285,
                    "end": 291,
                    "mention": "Fig. 2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 414,
                    "end": 421,
                    "mention": "Table 2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Through these practices, THJU has carried out successful drug supply management without drug shortages or drug delays. Up to now, there has been no nosocomial infection related to pharmacy.",
            "cite_spans": [],
            "section": "Practice 2: drug supply management",
            "ref_spans": []
        },
        {
            "text": "The off-label drug use may rise greater potential drug use risks, pharmacists emphasize on adverse drug reactions(ADR), use the \u201cAdverse Drug Reaction Monitoring System of Medical Institutions\u201d to monitor the adverse reactions of off-label drugs, evaluate the causal relationship of adverse drug reactions13 and feed back the evaluation results in time.",
            "cite_spans": [
                {
                    "start": 305,
                    "end": 307,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                }
            ],
            "section": "Practice 3: management of off-label drug use",
            "ref_spans": []
        },
        {
            "text": "At present, antiviral drugs for COVID-19 have not been approved for marketing, prescribing antiviral drugs, such as lopinavir/ritonavir and ribavirin, for patients with COVID-19 could be defined as off-label drug use, the treatment is lack of clinical experience. The incidence of severe ADR in off-label using was significantly higher than normal use,14 such as anaphylactic shock, drug-induced liver damage and induced epilepsy, was prone to occur in off-label drug use cases. Pharmacists carried out monitoring ADR, evaluated and analyzed the symptoms of patients, and provided doctors with ADR information. During treatment, few new serious ADR occurred. In addition, pharmacists participated in the multidisciplinary diagnosis and treatment of COVID-19 patients, conducted nutritional risk screening and designed nutritional support programs. During the outbreak, all COVID-19 patients were cured and discharged.",
            "cite_spans": [
                {
                    "start": 352,
                    "end": 354,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "Practice 3: management of off-label drug use",
            "ref_spans": []
        },
        {
            "text": "Timely pharmaceutical care are critical for treatment during the coronavirus pandemic. Pharmacists have made a pharmaceutical care procedure (Fig. 3\n)according to needs of different groups, provided updated treatment plans, monitored potential drug interactions, focus on special population medication and implement remote pharmaceutical service.",
            "cite_spans": [],
            "section": "Practice 4: pharmaceutical care",
            "ref_spans": [
                {
                    "start": 142,
                    "end": 148,
                    "mention": "Fig. 3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "The CNHC has released the \u201cDiagnosis and Treatment Guidelines for the New Coronavirus Infected Pneumonia\u201d, currently in its seventh update. To have a better grasp on the latest version of diagnosis and treatment plans for frontline physicians, pharmacists made a list of changes(Table 3\n).",
            "cite_spans": [],
            "section": "Practice 4: pharmaceutical care",
            "ref_spans": [
                {
                    "start": 279,
                    "end": 286,
                    "mention": "Table 3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "Pharmacists also provided a list of common risk warnings of potential drug interactions and reactions according to COVID-19 diagnosis and treatment plans combined with literatures (Table 4).",
            "cite_spans": [],
            "section": "Practice 4: pharmaceutical care",
            "ref_spans": [
                {
                    "start": 181,
                    "end": 188,
                    "mention": "Table 4",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "\nPregnant women, especially in middle and terminal pregnancy, are prone to develop into severe patients after infecting with COVID-1918. Gestational age, and whether to terminate the pregnancy after treatment has been considered in the therapy.16 Older adults are often associated with a variety of chronic diseases and have a higher risk of death if infected with COVID-19.19 Physiological characteristics and combination of drugs will change pharmacokinetics and affect the efficacy. Therefore, individualized pharmaceutical care have been provided in combination with physiological characteristics and disease progression.20\n",
            "cite_spans": [
                {
                    "start": 133,
                    "end": 135,
                    "mention": "18",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 244,
                    "end": 246,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 374,
                    "end": 376,
                    "mention": "19",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 625,
                    "end": 627,
                    "mention": "20",
                    "ref_id": "BIBREF12"
                }
            ],
            "section": "Practice 4: pharmaceutical care",
            "ref_spans": []
        },
        {
            "text": "Pharmacists used \u201cPrescription Approval & Prospective Audit and Feedback System\u201d to carry out online prescription reviewing. The THJU network and \u201cPharmacists by Your Side\u201d (Wechat Subscription) was applied to provide free drug consultation to resolve problems of drug use. Pharmacists publicize the prevention and control of COVID-19 to the public free of charge online. These practices of online pharmacy services provide accessible pharmaceutical care and help to reduce the risk of cross-infection during unnecessary hospital visits.",
            "cite_spans": [],
            "section": "Practice 4: pharmaceutical care",
            "ref_spans": []
        },
        {
            "text": "In the fight against the epidemic, hospitals are facing difficulties in personnel, drug supply and pharmaceutical care. The pharmaceutical department have established effective drug supply and pharmaceutical care practices, and provided a strong guarantee for epidemic prevention, control and treatment. On March 11, WHO has made assessment that COVID-19 could be characterized as a pandemic and many countries and regions are now experiencing the difficulties that our country once faced. Pharmacists summarize the management model and experience to provide reference for those who in the same predicament. Post-epidemic era, pharmacists should remain engaged in the coordinated efforts and be readily adaptive to changes required in drug supplying and pharmaceutical care.15, 16, 17\n",
            "cite_spans": [
                {
                    "start": 774,
                    "end": 776,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 778,
                    "end": 780,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 782,
                    "end": 784,
                    "mention": "17",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.",
            "cite_spans": [],
            "section": "Funding",
            "ref_spans": []
        },
        {
            "text": "None.",
            "cite_spans": [],
            "section": "Declarations of competing interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: List of THJU COVID-19 treatment drugs.9, 10, 11\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: List of items for Management of donated drugs.12(4)Safe working environment is an important condition to ensure the progress of diagnosis and treatment. In order to reduce the spread of the virus through person-to-person transmission during the coronavirus epidemic, outpatient pharmacy of THJU are disinfected 4 times everyday. Pharmacists of outpatient pharmacy also designed safety transfer devices to avoid contacting patients in drugs dispensing. Otherwise, pharmacists adjusted the route and time of drug transportation in the hospital and used designated elevators and vehicles for drug delivery.\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: List of changes in diagnosis and treatment plans for COVID-19.15,16\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 4: List of potential drug interactions and reactions.16,17\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Fig. 1: Workflow.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Fig. 2: Donations management process.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Fig. 3: Pharmaceutical care procedure.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Recent insights into 2019-nCoV: a brief but comprehensive review",
            "authors": [
                {
                    "first": "Q.",
                    "middle": [],
                    "last": "Han",
                    "suffix": ""
                },
                {
                    "first": "Q.",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Jin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Infect",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Standing Committee of the Ninth National People's Congress",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "The adverse drug reaction evaluation and case analysis by using Naranjo probability scale",
            "authors": [
                {
                    "first": "F.Y.",
                    "middle": [],
                    "last": "Zheng",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "Y.F.",
                    "middle": [],
                    "last": "Yao",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Chin Pharmaceut J",
            "volume": "47",
            "issn": "",
            "pages": "650-652",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Analysis of off-label drug uses in adverse drug events of our hospital",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Chin J D App M",
            "volume": "15",
            "issn": "",
            "pages": "46-49",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Pharmaceutical emergency guarantee difficulties and countermeasures for the prevention and control of outbreak of Novel Coronavirus Pneumonia(NCP)",
            "authors": [
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "G.F.",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Du",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin J Hosp Pharm",
            "volume": "40",
            "issn": "",
            "pages": "243-249",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "Novel coronavirus control and prevention strategy: pharmaceutical guidance and management strategy",
            "authors": [
                {
                    "first": "R.S.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "Y.H.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin Pharmaceut J",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "COVID-19 treatment protocol (drug information) compilation (First Edition), Cntrl S Pharm",
            "authors": [
                {
                    "first": "Y.G.",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                },
                {
                    "first": "Z.W.",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "L.H.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Recommendation for the diagnosis and treatment of novel coronavirus infection in children in Hubei (Trial version 1)",
            "authors": [
                {
                    "first": "D.C.",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "R.M.",
                    "middle": [],
                    "last": "Jin",
                    "suffix": ""
                },
                {
                    "first": "Z.S.",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin J Contemp Pediatr",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Pharmacological care strategy for antivirals in patients with COVID-19 complicated by underlying disorders",
            "authors": [
                {
                    "first": "R.R.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "Q.",
                    "middle": [],
                    "last": "Xu",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin J Hosp Pharm",
            "volume": "40",
            "issn": "",
            "pages": "1-7",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Hospital pharmacy administration and pharmaceutical care in the prevention and control of corona virus disease-19",
            "authors": [
                {
                    "first": "Y.F.",
                    "middle": [],
                    "last": "Rao",
                    "suffix": ""
                },
                {
                    "first": "J.H.",
                    "middle": [],
                    "last": "Guo",
                    "suffix": ""
                },
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Miao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Chin J Hosp Pharm",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Health commission of Jilin Province",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "International Pharmaceutical Federation",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "World Health Organization",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Improving emergency response collaboration and resource allocation by task network mapping and analysis",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Qi",
                    "suffix": ""
                },
                {
                    "first": "H.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Saf Sci",
            "volume": "70",
            "issn": "",
            "pages": "9-18",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "World Health Organization",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "National Health Commission of the People\u2019s Republic of China",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}